In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting
treatment paradigms towards increasingly personalized approaches. Liquid biopsies using …

Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the
heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …

Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new
promising noninvasive tool to detect biomarker in several cancers including lung cancer …

The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might
revolutionize cancer care with respect to early detection, identification of minimal residual …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Recent developments in massively parallel sequencing and digital genomic techniques
support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy'in …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …